Scholarlink

<p>Depression is increasingly recognized as a prevalent source of disability in individuals with Parkinson’s disease (PD), but its pathophysiology is not well understood. Neural activity in the basal ganglia, particularly the subthalamic nucleus, has been linked to depression in PD, but the role of the pallidum remains unclear. This retrospective study aimed to correlate preoperative depression symptoms with intraoperative resting-state neural activity recorded from the pallidum in <i>N</i> = 50 patients who underwent deep-brain stimulation (DBS) implantation surgery. Patients with clinically elevated depression symptoms exhibited elevated beta (13–30 Hz) power compared to patients without depression. Beta power, particularly high beta (20–30 Hz) power, was also associated with depression symptom severity, even when controlling for other demographic, clinical, pharmacological, and neurophysiological variables. These results suggest pallidal beta power as a potential biomarker of depression in PD and set the stage for tailoring DBS therapy to improve psychiatric symptoms in PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pallidal beta power is associated with depression in Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月22日

查看全文
  • Kara A. Johnson,
  • Patricia B. Coutinho,
  • Lauren E. Kenney,
  • Joshua K. Wong,
  • Justin D. Hilliard,
  • Kelly D. Foote,
  • Dawn Bowers,
  • Gregory M. Pontone,
  • Coralie de Hemptinne

摘要

Depression is increasingly recognized as a prevalent source of disability in individuals with Parkinson’s disease (PD), but its pathophysiology is not well understood. Neural activity in the basal ganglia, particularly the subthalamic nucleus, has been linked to depression in PD, but the role of the pallidum remains unclear. This retrospective study aimed to correlate preoperative depression symptoms with intraoperative resting-state neural activity recorded from the pallidum in N = 50 patients who underwent deep-brain stimulation (DBS) implantation surgery. Patients with clinically elevated depression symptoms exhibited elevated beta (13–30 Hz) power compared to patients without depression. Beta power, particularly high beta (20–30 Hz) power, was also associated with depression symptom severity, even when controlling for other demographic, clinical, pharmacological, and neurophysiological variables. These results suggest pallidal beta power as a potential biomarker of depression in PD and set the stage for tailoring DBS therapy to improve psychiatric symptoms in PD.